Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
HALO

HALO - Halozyme Therapeutics Inc Stock Price, Fair Value and News

50.27USD+0.61 (+1.23%)Delayed

Market Summary

HALO
USD50.27+0.61
Delayed
1.23%

HALO Alerts

  • 2 major insider sales recently.
  • Big jump in Earnings (Y/Y)

HALO Stock Price

View Fullscreen

HALO RSI Chart

HALO Valuation

Market Cap

6.4B

Price/Earnings (Trailing)

20.07

Price/Sales (Trailing)

7.41

EV/EBITDA

18.34

Price/Free Cashflow

15.11

HALO Price/Sales (Trailing)

HALO Profitability

EBT Margin

45.44%

Return on Equity

179.3%

Return on Assets

17.31%

Free Cashflow Yield

6.62%

HALO Fundamentals

HALO Revenue

Revenue (TTM)

863.0M

Rev. Growth (Yr)

20.81%

Rev. Growth (Qtr)

-14.85%

HALO Earnings

Earnings (TTM)

318.8M

Earnings Growth (Yr)

93.92%

Earnings Growth (Qtr)

-10.03%

Breaking Down HALO Revenue

Last 7 days

0.7%

Last 30 days

12.4%

Last 90 days

24.5%

Trailing 12 Months

43.7%

How does HALO drawdown profile look like?

HALO Financial Health

Current Ratio

6.64

Debt/Equity

8.44

Debt/Cashflow

0.29

HALO Investor Care

Buy Backs (1Y)

3.35%

Diluted EPS (TTM)

2.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024863.0M000
2023705.0M773.7M780.7M829.3M
2022471.6M487.5M580.6M660.1M
2021331.3M412.5M463.0M443.3M
2020164.4M180.5M199.6M267.6M
2019177.9M181.9M202.6M196.0M
2018317.9M319.4M281.2M151.9M
2017133.8M134.2M166.1M316.6M
2016146.7M146.7M146.7M146.7M
2015105.9M120.8M138.1M146.7M
201454.9M58.9M57.5M75.3M
201346.7M53.4M64.1M54.8M
201256.0M40.6M22.9M42.3M
201117.7M37.7M57.2M56.1M
2010013.7M13.6M13.6M
200900013.7M

Tracking the Latest Insider Buys and Sells of Halozyme Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 12, 2024
posard matthew l.
sold
-506,190
50.619
-10,000
-
Jun 11, 2024
posard matthew l.
sold
-500,110
50.011
-10,000
-
May 22, 2024
labarre michael j.
sold
-453,840
45.384
-10,000
svp, chief technical officer
May 22, 2024
labarre michael j.
acquired
81,100
8.11
10,000
svp, chief technical officer
May 21, 2024
labarre michael j.
acquired
81,100
8.11
10,000
svp, chief technical officer
May 21, 2024
labarre michael j.
sold
-451,640
45.164
-10,000
svp, chief technical officer
Apr 25, 2024
connaughton bernadette
acquired
-
-
6,501
-
Apr 25, 2024
posard matthew l.
acquired
-
-
6,501
-
Apr 25, 2024
duncan barbara gayle
acquired
-
-
6,501
-
Apr 25, 2024
henderson jeffrey william
acquired
-
-
6,501
-

1–10 of 50

Which funds bought or sold HALO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
reduced
-2.78
191
89,154
0.01%
Jun 04, 2024
DekaBank Deutsche Girozentrale
added
9.81
375,000
2,220,000
-%
Jun 04, 2024
Aurora Investment Counsel
added
20.97
223,014
1,828,520
1.05%
May 28, 2024
Boston Partners
added
14.12
5,282,640
25,500,200
0.03%
May 28, 2024
Verity Asset Management, Inc.
added
36.54
532,050
1,590,140
0.89%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
163,000
1,790,000
0.02%
May 24, 2024
Cetera Investment Advisers
new
-
170,776
170,776
-%
May 24, 2024
Cetera Investment Advisers
new
-
772,025
772,025
-%
May 21, 2024
LRI Investments, LLC
new
-
1,709
1,709
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
reduced
-54.98
-1,008,520
990,477
0.13%

1–10 of 37

Are Funds Buying or Selling HALO?

Are funds buying HALO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HALO
No. of Funds

Unveiling Halozyme Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
10.04%
13,259,514
SC 13G/A
Feb 12, 2024
artisan partners limited partnership
5.1%
6,689,058
SC 13G/A
Feb 01, 2024
invesco ltd.
2.1%
2,816,427
SC 13G/A
Jan 23, 2024
blackrock inc.
14.1%
18,629,818
SC 13G/A
Jun 09, 2023
vanguard group inc
10.27%
13,528,630
SC 13G/A
Feb 10, 2023
invesco ltd.
5.2%
7,036,951
SC 13G
Feb 10, 2023
blackrock inc.
14.2%
19,196,061
SC 13G/A
Feb 10, 2023
artisan partners limited partnership
5.3%
7,140,953
SC 13G/A
Feb 09, 2023
vanguard group inc
9.84%
13,303,847
SC 13G/A
Jan 26, 2023
blackrock inc.
13.6%
18,214,071
SC 13G/A

Recent SEC filings of Halozyme Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 18, 2024
144
Notice of Insider Sale Intent
Jun 14, 2024
4
Insider Trading
Jun 13, 2024
4
Insider Trading
Jun 11, 2024
144
Notice of Insider Sale Intent
May 22, 2024
144
Notice of Insider Sale Intent
May 22, 2024
4
Insider Trading
May 21, 2024
144
Notice of Insider Sale Intent
May 07, 2024
10-Q
Quarterly Report
May 07, 2024
8-K
Current Report
Apr 29, 2024
4
Insider Trading

Peers (Alternatives to Halozyme Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
0.28% 3.53%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.5B
2.0B
2.99% -23.67%
-58.61
9.71
75.20% 68.82%
16.0B
2.5B
8.50% -12.61%
77.77
6.46
13.74% 186.89%
13.8B
3.8B
7.60% -2.83%
18.51
3.66
8.58% 129.81%
MID-CAP
5.2B
107.9M
-8.24% 83.94%
-9.45
48.09
54.84% -28.31%
4.9B
524.1M
-2.95% -55.09%
-11.65
9.28
394.93% 39.61%
3.6B
251.0M
-0.68% -10.56%
-12.18
14.38
73.58% -86.73%
2.9B
240.7M
-4.80% -33.39%
-6.19
12.77
-1.03% -213.92%
2.5B
813.8M
0.54% -38.22%
-1.4K
3.02
56.43% 98.83%
1.9B
996.6M
5.92% 71.39%
-4.85
1.94
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.22% 22.70%
27.15
4.3
60.38% -34.49%
468.2M
881.7K
-2.64% 488.84%
-13.87
481.06
-77.61% 33.36%
221.8M
4.2M
-28.67% 45.58%
-1.78
53.32
-66.30% 48.24%
19.9M
2.1M
16.67% 230.00%
-0.86
7.61
-13.45% 69.54%

Halozyme Therapeutics Inc News

Latest updates
Defense World4 hours ago
Yahoo Finance17 Jun 202401:40 pm
Yahoo Movies Canada15 Jun 202412:07 am

Halozyme Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-14.8%19623021622116218120915211710211613689.0012265.0055.0025.0054.0046.0039.0057.00
Costs and Expenses-22.2%10012912812710810712611842.0045.0040.0043.0038.0044.0025.0026.0029.0086.0071.0053.0054.00
  S&GA Expenses-6.6%35.0038.0035.0039.0037.0038.0034.0057.0014.0014.0013.0012.0011.0010.0012.0011.0013.0024.0018.0017.0018.00
  R&D Expenses-10.4%19.0021.0017.0020.0018.0023.0017.0015.0012.0010.008.008.009.007.008.009.0010.0045.0030.0034.0031.00
EBITDA Margin7.2%0.49*0.46*0.44*0.41*0.36*0.41*0.43*0.50*0.65*0.58*0.61*0.60*---------
Interest Expenses-13.7%5.005.005.004.005.005.008.003.002.002.002.002.002.005.005.005.005.004.002.003.003.00
Income Taxes21.3%19.0016.0020.0018.0013.0013.0012.007.0014.00-11.96-1420.000.000.000.000.000.00-0.060.000.000.00
Earnings Before Taxes-5.1%96.0010110293.0052.0071.0074.0030.0074.0055.0074.0092.0028.0073.0036.0026.00-6.09-34.46-25.00-14.612.00
EBT Margin8.2%0.45*0.42*0.41*0.37*0.32*0.38*0.40*0.48*0.63*0.56*0.58*0.56*---------
Net Income-10.0%77.0085.0082.0075.0040.0058.0062.0023.0060.0067.0021791.0028.0073.0036.0026.00-6.10-34.40-25.01-14.622.00
Net Income Margin8.8%0.37*0.34*0.33*0.30*0.26*0.31*0.36*0.75*0.92*0.91*0.88*0.55*---------
Free Cashflow26.2%12610012968.0076.0080.0069.0039.0047.0082.0012136.00---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets6.2%1,8421,7331,8931,8101,6991,8421,8651,7811,1621,1041,1851,026967580524527492566370418429
  Current Assets17.0%8747468797666157396535429899261,0171,000942555499500468543342392409
    Cash Equivalents39.1%16511827422197.0023514891.0011811949244750014866.0013410512160.0068.0061.00
  Inventory32.1%16912812913210810010398.0048.0054.0056.0059.0058.0061.0058.0048.0041.0029.0036.0044.0031.00
  Net PPE9.9%42.0038.00---------10.0010.0011.0010.0011.0012.0011.0015.0015.0015.00
  Goodwill0%417417417417416409199199-------------
Liabilities0.9%1,6641,6491,6431,6591,6341,672---------------
  Current Liabilities17.0%13211211511692.0013110920011211711311410742127.0026.0042.0086.00108135139
  Long Term Debt0.1%1,5011,4991,4981,4961,4941,4931,4911,147788787786786785-3943903873839.0014.0019.00
    LT Debt, Current------13.0013.0099.0090.0089.0089.0089.0089.00397--3.0020.0055.0071.0087.00
    LT Debt, Non Current0.1%1,5011,4991,4981,4961,4941,4931,491--787-----------
Shareholder's Equity112.2%17884.0024915166.0017097.0029326019728212068.0015199.0010658.0092.00245260260
  Retained Earnings84.8%16791.0022214066.0014386.0024.001.00-58.91-125-342-433-474-547-583-609-603-569-544-529
  Additional Paid-In Capital389.6%12.002.0026.0012.00-27.0013.00271262256407462501625646688668695814804789
Shares Outstanding0.3%127127132132135135137138138141142142---------
Float----3,500---5,100---5,600---2,900---2,500-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations26.5%129,427102,354132,41166,84286,96482,45369,63540,22547,79782,516121,73936,88958,29650,9206,0843,294-4,844-26,625-29,588-24,786-4,424
  Share Based Compensation2.2%9,8749,6649,3689,6227,9667,2236,7975,6354,7425,1265,3995,3724,9234,1964,2204,2574,5317,2298,2399,8339,475
Cashflow From Investing-897.2%-82,681-8,291-83,45054,994-60,162-1,746-1,008-434,946-49,305-299,469-16,954-44,616-45,25058,441-30,09511,89938,109-122,81840,99947,45728,813
Cashflow From Financing99.8%-489-249,9204,1012,446-164,6146,329-12,400367,818624-156,011-60,068-44,757338,701-27,399-43,85413,593-48,624210,420-19,250-16,225-21,730
  Buy Backs-100.0%-252,300--150,0831.00200,001--160,32164,71648,84276,17938,89658,9021,99651,574----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

HALO Income Statement

2024-03-31
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues  
Total revenues$ 195,879$ 162,143
Operating expenses  
Cost of sales28,32935,170
Amortization of intangibles17,76317,835
Research and development19,11117,979
Selling, general and administrative35,13437,357
Total operating expenses100,337108,341
Operating income95,54253,802
Other income (expense)  
Investment and other income, net4,9932,979
Interest expense(4,507)(4,543)
Net income before income taxes96,02852,238
Income tax expense19,20512,623
Net income$ 76,823$ 39,615
Earnings per share  
Basic (USD per share)$ 0.61$ 0.29
Diluted (USD per share)$ 0.60$ 0.29
Weighted average common shares outstanding  
Basic (shares)126,941135,027
Diluted (shares)128,887137,900
Royalties  
Revenues  
Total revenues$ 120,593$ 99,640
Product sales, net  
Revenues  
Total revenues58,58360,794
Revenues under collaborative agreements  
Revenues  
Total revenues$ 16,703$ 1,709

HALO Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 164,627$ 118,370
Marketable securities, available-for-sale298,824217,630
Accounts receivable, net and contract assets195,902234,210
Inventories, net168,541127,601
Prepaid expenses and other current assets45,69048,613
Total current assets873,584746,424
Property and equipment, net78,07174,944
Prepaid expenses and other assets17,31917,816
Goodwill416,821416,821
Intangible assets, net455,116472,879
Deferred tax assets, net6164,386
Total assets1,841,5271,733,270
Current liabilities  
Accounts payable13,32511,816
Accrued expenses118,314100,678
Total current liabilities131,639112,494
Long-term debt, net1,500,8791,499,248
Other long-term liabilities31,20137,720
Total liabilities1,663,7191,649,462
Commitments and contingencies (Note 11)
Stockholders’ equity  
Preferred stock - $0.001 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock - $0.001 par value; 300,000 shares authorized; 127,186 and 126,770 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively127127
Additional paid-in capital11,7942,409
Accumulated other comprehensive loss(1,486)(9,278)
Retained earnings167,37390,550
Total stockholders’ equity177,80883,808
Total liabilities and stockholders’ equity$ 1,841,527$ 1,733,270
HALO
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://halozyme.com
 INDUSTRYBiotechnology
 EMPLOYEES393

Halozyme Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Halozyme Therapeutics Inc? What does HALO stand for in stocks?

HALO is the stock ticker symbol of Halozyme Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Halozyme Therapeutics Inc (HALO)?

As of Tue Jun 18 2024, market cap of Halozyme Therapeutics Inc is 6.4 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HALO stock?

You can check HALO's fair value in chart for subscribers.

What is the fair value of HALO stock?

You can check HALO's fair value in chart for subscribers. The fair value of Halozyme Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Halozyme Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HALO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Halozyme Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HALO is over valued or under valued. Whether Halozyme Therapeutics Inc is cheap or expensive depends on the assumptions which impact Halozyme Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HALO.

What is Halozyme Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jun 18 2024, HALO's PE ratio (Price to Earnings) is 20.07 and Price to Sales (PS) ratio is 7.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HALO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Halozyme Therapeutics Inc's stock?

In the past 10 years, Halozyme Therapeutics Inc has provided 0.173 (multiply by 100 for percentage) rate of return.